Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Simple CUT&Tag adaptation gives information about genetic regulatory elements in formalin-fixed tumor samples
New immunotherapies improve outcomes, but access to care and clinical trials for many still lags, notes an AACR cancer report. [VIDEO]
Team uses large-scale proteogenomic changes to identify which ovarian cancer patients should look beyond standard treatment options.
Vallurupalli, of Dana-Farber Cancer Institute, researches blood cancers and is passionate about equitable access to precision cancer care.
ComboMATCH comprises numerous clinical trials that will evaluate different drug combinations.
Biomarker testing can help patients avoid chemo and radiation, but it isn’t available to all, according to CancerCare findings.
A small group of adults in remission had persisting mutations that predicted their risk of death from having the cancer return.
MatchMiner shortens the time it takes to identify appropriate precision medicine trials for individual patients.
University of California San Francisco researchers uncover common immune microenvironments across different types of cancer.
A look back at some of the most important science and treatment news Cancer Health covered this year.
A new generation of precision cancer therapies are easier to tolerate than traditional treatment.
Most never smokers who develop lung cancer have tumor mutations that make them eligible for precision medicine.
Data from early clinical trials suggest new precision cancer treatments are on the horizon.
For Childhood Cancer Awareness Month, the National Cancer Institute’s Director Dr. Ned Sharpless reflects on childhood cancer progress.
For people with cancer being treated with chemo drugs in the class fluoropyrimidines, DPD testing can be lifesaving.
Genomic testing can help customize treatment to target tumors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.